27 January 2020 - China has started to regularly update its National Reimbursement Drug List which could lead to new opportunities for innovative drug manufacturers to foray into the Chinese market, say researchers.

Due to China updating its National Reimbursement Drug List (NRDL) to include 70 new medicines with an average price cut of 61 percent in November 2019, there is a promising opportunity for innovative drug manufacturers to foray into the second-largest pharmaceutical market in the world after the US in terms of value, says a new report.

With China frequently updating the NRDL every year, there are more opportunities to pharma companies for inclusion in the NRDL list, the researchers say.

Read European Pharmaceutical Review article